Outcome of older patients with acute myeloid leukemia in first relapse

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

(2011) Hassan Farhat et al.   AMERICAN JOURNAL OF HEMATOLOGY

FLT3/ITD AML and the law of unintended consequences

(2011) M. Levis   BLOOD

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

(2011) R. Itzykson et al.   HAEMATOLOGICA

FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype

(2011) K. Wagner et al.   HAEMATOLOGICA

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

(2011) P Chevallier et al.   LEUKEMIA

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine

(2010) Thomas Prebet et al.   CANCER

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

(2010) S. Kurosawa et al.   HAEMATOLOGICA

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

(2010) Cecile Pautas et al.   JOURNAL OF CLINICAL ONCOLOGY

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

(2009) C. Haferlach et al.   BLOOD

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin

(2009) P Chevallier et al.   LEUKEMIA

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

(2009) Farhad Ravandi et al.   LEUKEMIA RESEARCH

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

(2008) Roberto Stasi et al.   CANCER TREATMENT REVIEWS

Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia

(2008) Patrice Chevallier et al.   JOURNAL OF CLINICAL ONCOLOGY

Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly

(2008) J. Laubach et al.   ONCOLOGIST